Evaluation of clinical benefit in dermatological therapy. Evaluation of therapy from the physician's und patient's perspective in psoriasis and atopic dermatitis;Therapeutischer nutzen in der dermatologischen behandlung. Bewertung von therapieerfolg aus arzt- und patientenperspektive bei psoriasis und atopischer dermatitis

Hautarzt

Volumn 56, Issue 9, 2005, Pages 839-846

  Zschocke, I ^a   Hammelmann, U ^b   Augustin, M ^c  

^a IFKS   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Cost vs. value aspects; Evalution of value; Patient expectation; Patient related outcome; therapy goals

Indexed keywords

ANTIALLERGIC AGENT; ANTIPSORIASIS AGENT;

ARTICLE; ATOPIC DERMATITIS; CONTROLLED STUDY; DISTRESS SYNDROME; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MEDICAL PERSONNEL; MEDICAL STAFF; PSORIASIS; PSORIASIS VULGARIS; QUESTIONNAIRE; SIDE EFFECT; SYMPTOM;

ADULT; ATTITUDE OF HEALTH PERSONNEL; ATTITUDE TO HEALTH; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SATISFACTION; PSORIASIS; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 24044465523     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-005-0898-5     Document Type: Article

References (12)

1. Augustin M (2001) Recording of quality of life in dermatological studies. Guidelines of the Subcommission "Pharmacoeconomics and Quality of Life". Hautarzt 52 (8):697-700
2. Augustin M, Zschocke I, Seidenglanz K et al. (2000) Validation and clinical results of the FLQA-d, a quality of life questionnaire for patients with chronic skin diseases. Dermatol Psychosom 1 (1):12-17
3. Finlay AY, Khan GK (1994) Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol. 19 (3):210-216
4. Krueger GG, Feldman SR, Camisa C et al. (2000) Two considerations for patients with Psoriasis and their clinicians: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 43:281-285
5. McAlister RO et al. (2002) Patient and physician perspective vary on atopic dermatitis. Cutis 69:461-466
6. McKenna KE, Stern RS (1996) The outcomes movement and new measures of the severity of psoriasis. J Am Acad Dermatol 34:534-538
7. Paller A et al. (2002) Perceptions of physicians and pediatric patients about atopic dermatitis, its impact, and its treatment. Clin Ped June:323-332
8. Rapp SR, Feldman SR, Exum ML et al. (1999) Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41 (3 Pt 1):401-407
9. Rychlik R, Rusche H, Augustin M (2004) Systematik der Nutzenbewertung von Arzneimitteln. Gesundheitsökonomie und Qualitätsmanagement 04/04:245-252
10. Sackett DL, Chambers LW, MacPherson AS et al. (1977) The development and application of indices of health: general methods and summary of results. Am J Public Health 67:423-128
11. Sartorius N (1993) A WHO-method for the assessment of health-related quality of life (WHO-QOL). In: Walker S, Rosser M (eds) Quality of life assessment: key issues in the 1990's. Kluwer, Dordrecht, pp 201-203
12. Van de Kerkhof PC, de Hoop D, de Korte J et al. (2000) Patient compliance and disease management in the treatment of psoriasis in Netherlands. Dermatol 200 (4):292-298